Clinical trial
Thymoglobulin (ATG) Dose Finding Study
NCT00409695 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00409695 |
|---|---|
| Title | Thymoglobulin (ATG) Dose Finding Study |
| Official title | Dose Finding Study of Thymoglobulin (ATG) in Patients With Steroid-Refractory Acute Graft Versus Host Disease (aGVHD) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genzyme, a Sanofi Company Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Graft vs Host Disease |
| Intervention type | Drug |
| Interventions | Low Dose Thymoglobulin (ATG), High Dose Thymoglobulin (ATG) |
| Enrollment | 1 |
| Start date | Dec 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Dec 11, 2006 |
| Last update posted | Jan 23, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: